Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability

Table 2

Response to sorafenib treatment in patients with advanced HCC according to the intention to treat analysis (ITT) and in patients treated for at least 3 months.

Response	ITT, 𝑁 (%)	Evaluable pt.* N(%)
Complete response	—	—
Partial response	7 (9.3)	7 (21.9)
Stable disease	18 (24.0)	18 (56.2)
Progressive disease	8 (10.7)	8 (25)
Not assessable	1 (1.3)	1 (3)
Disease control rate	33.3%	78.1%

∗Response evaluated in patients completing 3 months of sorafenib therapy.